Research
Hormonal
Semaglutide is being investigated for its potential in combating obesity.
Practitioners should stay informed about the potential use of semaglutide for obesity management.
StrongSupportsmedium confidence
It is currently being investigated for its potential in combating obesity.
Why this rating
The ongoing investigation implies a strong basis for potential effectiveness.
Source
Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity
Raghav Gupta et al. · Current Signal Transduction Therapy · 2025
DOI 10.2174/0115743624346660250317013032
otherCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →